Search Results - "Ayeni, Deborah"

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic by Politi, Katerina, Ayeni, Deborah, Lynch, Thomas

“…The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase…”
Get full text

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo by Foggetti, Giorgia, Li, Chuan, Cai, Hongchen, Hellyer, Jessica A, Lin, Wen-Yang, Ayeni, Deborah, Hastings, Katherine, Choi, Jungmin, Wurtz, Anna, Andrejka, Laura, Maghini, Dylan G, Rashleigh, Nicholas, Levy, Stellar, Homer, Robert, Gettinger, Scott N, Diehn, Maximilian, Wakelee, Heather A, Petrov, Dmitri A, Winslow, Monte M, Politi, Katerina

“…In lung adenocarcinoma, oncogenic mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth…”
Get more information

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations by Starrett, Jacqueline H, Guernet, Alexis A, Cuomo, Maria Emanuela, Poels, Kamrine E, van Alderwerelt van Rosenburgh, Iris K, Nagelberg, Amy, Farnsworth, Dylan, Price, Kristin S, Khan, Hina, Ashtekar, Kumar Dilip, Gaefele, Mmaserame, Ayeni, Deborah, Stewart, Tyler F, Kuhlmann, Alexandra, Kaech, Susan M, Unni, Arun M, Homer, Robert, Lockwood, William W, Michor, Franziska, Goldberg, Sarah B, Lemmon, Mark A, Smith, Paul D, Cross, Darren A E, Politi, Katerina

“…Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for -mutant lung cancer, yet…”
Get full text

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma by Pirazzoli, Valentina, Ayeni, Deborah, Meador, Catherine B, Sanganahalli, Basavaraju G, Hyder, Fahmeed, de Stanchina, Elisa, Goldberg, Sarah B, Pao, William, Politi, Katerina

“…The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost…”
Get full text

Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma by Robles-Oteiza, Camila, Ayeni, Deborah, Levy, Stellar, Homer, Robert J, Kaech, Susan M, Politi, Katerina

“…Conditional ablation of defined cell populations in vivo can be achieved using genetically engineered mice in which the human diphtheria toxin (DT) receptor…”
Get full text

Iron and zinc levels in Vigna unguiculata (L.) Walp under varying phosphorus and fixed nitrogen treatment conditions by Ayeni, Deborah F., Ikwebe, Joseph, Onyezili, Francis N.

“…Using phosphate fertilizer (particularly at high levels) to improve the phosphorus (P) level of soils during the cultivation of legumes and other cereals…”
Get full text

Julia-Kocienski Approach to Trifluoromethyl-Substituted Alkenes1 by Ayeni, Deborah O, Mandal, Samir K, Zajc, Barbara

“…A Julia-Kocienski approach to trifluoromethyl-substituted alkenes was evaluated in the reactions of 1,3-benzothiazol-2-yl, 1-phenyl-1H-tetrazol-5-yl, and…”
Get full text

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors by Ayeni, Deborah, Miller, Braden, Kuhlmann, Alexandra, Ho, Ping-Chih, Robles-Oteiza, Camila, Gaefele, Mmaserame, Levy, Stellar, de Miguel, Fernando J, Perry, Curtis, Guan, Tianxia, Krystal, Gerald, Lockwood, William, Zelterman, Daniel, Homer, Robert, Liu, Zongzhi, Kaech, Susan, Politi, Katerina

“…Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer;…”
Get full text

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer by Ayeni, Deborah, Politi, Katerina, Goldberg, Sarah B

“…Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M)…”
Get full text

Julia–Kocienski approach to trifluoromethyl-substituted alkenes by Ayeni, Deborah O., Mandal, Samir K., Zajc, Barbara

“…A Julia–Kocienski approach to trifluoromethyl-substituted alkenes was evaluated in the reactions of 1,3-benzothiazol-2-yl, 1-phenyl-1H-tetrazol-5-yl, and…”
Get full text

Abstract 1094: Genetic determinants of EGFR -driven lung cancer growth and therapeutic response in v ivo by Foggetti, Giorgia, Li, Chuan, Cai, Hongchen, Lin, Wen-Yang, Ayeni, Deborah, Hastings, Katherine, Andrejka, Laura, Maghini, Dylan, Homer, Robert, Petrov, Dmitri A., Winslow, Monte M., Politi, Katerina

“…Abstract Oncogenic alterations in the Epidermal Growth Factor Receptor (EGFR) gene are found in ~15% of lung adenocarcinomas (LUADs). EGFR mutations predict…”
Get full text

JuliaaKocienski approach to trifluoromethyl-substituted alkenes by Ayeni, Deborah, Mandal, Samir, Zajc, Barbara

“…A JuliaaKocienski approach to trifluoromethyl-substituted alkenes was evaluated in the reactions of 1,3-benzothiazol-2-yl, 1-phenyl-1H-tetrazol-5-yl, and…”
Get full text

Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations by Starrett, Jacqueline H., Guernet, Alexis, Cuomo, Maria Emanuela, Poels, Kamrine, van Alderwerelt van Rosenburgh, Iris K., Nagelberg, Amy, Farnsworth, Dylan, Price, Kristin, Khan, Hina, Ashtekar, Kumar D., Gaefele, Mmaserame, Ayeni, Deborah, Stewart, Tyler F., Kuhlmann, Alexandra, Kaech, Susan M., Unni, Arun M., Homer, Robert, Lockwood, William W., Michor, Franziska, Goldberg, Sarah B., Lemmon, Mark A., Smith, Paul, Cross, Darren, Politi, Katerina

“…Abstract only Osimertinib, a mutant‐specific third generation EGFR TKI, is emerging as the preferred first‐line therapy for EGFR mutant lung cancer. Despite…”
Get full text

Julia-Kocienski Approach to Trifluoromethyl-Substituted Alkenes 1 by Ayeni, Deborah O, Mandal, Samir K, Zajc, Barbara

“…A Julia-Kocienski approach to trifluoromethyl-substituted alkenes was evaluated in the reactions of 1,3-benzothiazol-2-yl, 1-phenyl-1 -tetrazol-5-yl, and 1-…”
Get full text

Modulation of the Immune System as a Strategy to Treat Lung Adenocarcinoma by Ayeni, Deborah Opeyemi

“…Lung cancer is the leading cause of cancer-related deaths worldwide and there are currently no curative treatment options for patients with advanced-stage…”
Get full text

Abstract 2072: The role of the integrated stress response proteins GCN2 and ATF4 in autophagy and tumor migration by Lehman, Stacey L., Sayers, Carly M., Ye, Jiangbin, Hart, Lori S., Ayeni, Deborah O., Koong, Albert, Koumenis, Constantinos

“…Abstract The Integrated Stress Response (ISR) is a program elicited by mammalian cells to attenuate global translation in response to a variety of stressors…”
Get full text